Navigation Links
Dendreon Reports Third Quarter 2008 Financial Results
Date:11/7/2008

onferences that

will be webcast. Both conferences will occur later this month and

include:

o Rodman & Renshaw 10th Annual Healthcare Conference

o Lazard Capital Markets 5th Annual Healthcare Conference

"The interim analysis of our Phase 3 IMPACT trial was an important milestone for us. We were encouraged to see a 20 percent reduction in the risk of death in the PROVENGE arm versus placebo at the time of this analysis in a patient population that currently has few appealing treatment options available," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon Corporation. "Importantly, the results from this interim analysis are consistent with those from our previous Phase 3 studies at a similar follow-up time, and we are looking forward to the final analysis of the IMPACT trial in the middle of next year."

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
5. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
6. Dendreon Reports First Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Announces Closing of Registered Direct Offering
9. Dendreon Announces $47 Million Registered Direct Offering
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 - Elsevier, a world-leading provider of ... announced the publication of a recent study in ... human blastocysts showing that those with an abnormal chromosomal ... they have developed to blastocysts, thereby classifying the risk ... study the same group has undertaken a retrospective study, ...
(Date:5/17/2013)... 2013  Cellular Biomedicine Group (OTCQB: CBMG) today ... the total projected enrollment required for its Phase ... efficacy of the medical technology haMPC (Human Adipose-derived ... To date the trial has had no Severe ... I open label clinical research trial for KOA, ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( says skin ... known to react more aggressively when hormones change, and acne ... other acne causing factors like P.acnes bacteria and excess dirt ... unsightly acne scars. Adult acne treatment, Probiotic Action shares new ... to reduce and prevent acne scarring. , In order to ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 IAC Industries wants ... a start up laboratory needing to set up and furnish ... to a larger facility within a year’s time. How does ... that the laboratory is temporary? What is efficient and cost-effective? ... modular workstations from IAC Industries. The planners at DisperSol determined ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... YORK, Feb. 24, 2011 Reportlinker.com announces that ... its catalogue: Propylene Oxide: 2010 ... http://www.reportlinker.com/p0152026/Propylene-Oxide-2010-World-Market-Outlook-And-Forecast.html The report analyzes ... North America and Latin America. It provides the ...
... 24, 2011 Reportlinker.com announces that a new ... Global Marine Biotechnology Industry ... This report analyzes the Global markets for ... product segments- Marine Biomaterials, Marine Bioactive Substances, and ...
... Feb. 24, 2011 Palatin Technologies, Inc. (NYSE Amex: ... public offering of 23,000,000 units, consisting of 23,000,000 shares of ... of its common stock and Series B Warrants to purchase ... the public of $1.00 per unit. Palatin expects that the ...
Cached Biology Technology:Reportlinker Adds Propylene Oxide: 2010 World Market Outlook and Forecast 2Reportlinker Adds Global Marine Biotechnology Industry 2Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 2Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 3
(Date:5/16/2013)... NEW YORK , May 16, 2013 ... market research report is available in its ... Market Forecast & Opportunities, 2018 ... data protection and old security practises such ... driven the growth of biometric technologies in ...
(Date:5/15/2013)... touting its benefit in moderating gout risk, new research ... not reduce uric acid (urate) levels to a clinically ... supplementation, alone or in combination with allopurinol, appears to ... in gout patients according to the results published in ... & Rheumatism . , Gout is an inflammatory ...
(Date:5/15/2013)... PHILADELPHIA In the largest clinical trial to date ... BRCA 1/2 carriers with diseases other than breast and ... be effective against advanced pancreatic and prostate cancers. Results ... School of Medicine at the University of Pennsylvania and ... presented during the American Society of Clinical Oncology,s annual ...
Breaking Biology News(10 mins):Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7Vitamin C does not lower uric acid levels in gout patients 2PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... Berkeley Girls in homes without a biological father ... according to a new study led by researchers at the ... The findings, to be published Sept. 17 in the ... a biologically related father in the home predicted earlier breast ...
... More than 100 marine scientists, policy makers and members ... network of observatories monitoring Europe,s seas, at the ... Observatories,. This will give reliable, long-term data to underpin ... fisheries, aquaculture, energy, shipping, as well as tourism and ...
... CORVALLIS, Ore. Researchers at Oregon State University have ... a type of nanostructure that has gained significant ... surface area in microreactors. The findings, announced in ... door to important new nanotech applications in production of ...
Cached Biology News:Father absence linked to earlier puberty among certain girls 2Father absence linked to earlier puberty among certain girls 3Father absence linked to earlier puberty among certain girls 4Watch your seas: Marine scientists call for European marine observatory network 2'Nanosprings' offer improved performance in biomedicine, electronics 2
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... supernates and serum. Each kit contains sufficient ... 96-well plates, provided that the following conditions ...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Blimp-1 (H-150)...
SCP-1 (P-17)...
Biology Products: